ALRN:NSD-Aileron Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.14

Change

-0.05 (-4.20)%

Market Cap

USD 0.11B

Volume

0.77M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Watertown, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-4.60 (-2.82%)

USD65.51B 109.35 N/A
VRTX Vertex Pharmaceuticals Incorpo..

-2.11 (-0.98%)

USD55.66B 20.49 14.38
REGN Regeneron Pharmaceuticals, Inc

+5.59 (+1.13%)

USD52.92B 16.28 12.68
BNTX BioNTech SE

+18.64 (+10.15%)

USD44.37B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.38 (+0.81%)

USD37.67B 55.32 39.57
BGNE BeiGene, Ltd

-8.65 (-2.77%)

USD28.69B N/A N/A
SGEN Seagen Inc

-3.56 (-2.55%)

USD25.31B 38.92 34.59
RPRX Royalty Pharma plc

+0.52 (+1.27%)

USD24.87B 22.60 14.92
GMAB Genmab A/S

-0.16 (-0.43%)

USD24.33B 26.59 3.07
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ALRN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.62% 69% D+ 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.62% 69% D+ 56% F
Trailing 12 Months  
Capital Gain 102.59% 83% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 102.59% 83% B 76% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -2.32% 29% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.32% 29% F 19% F
Risk Return Profile  
Volatility (Standard Deviation) 98.18% 28% F 16% F
Risk Adjusted Return -2.37% 31% F 23% F
Market Capitalization 0.11B 19% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.24 25% F 20% F
Price / Cash Flow Ratio -5.25 39% F 68% D+
EV/EBITDA 0.05 87% B+ 98% A+
Management Effectiveness  
Return on Equity -150.00% 15% F 7% F
Return on Invested Capital -143.34% 9% F 5% F
Return on Assets -59.84% 10% F 3% F
Debt to Equity Ratio 1.80% 74% C 86% B
Technical Ratios  
Short Ratio 1.25 78% C+ 68% D+
Short Percent 2.57% 83% B 58% F
Beta 2.74 5% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.